Rollups

Supplier scorecards

28 suppliers, 6,584 reports, 1,154 batches. Each scorecard is arithmetic over the records the index holds for that supplier — median purity and its interquartile range, reproducibility across repeat tests of one lot, divergence between the supplier's own certificate and independent measurement, documentation completeness, and the provenance mix of the samples tested.

28 suppliers6,584 reportsindex median 99.08 %

Read this table the way the data allows

Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

Two further constraints on this table specifically. First, purity barely discriminates: nineteen of 28 supplier medians fall inside a 1.4 pp band, which is not much wider than the disagreement between two laboratories testing the same vial. Second, coverage is wildly uneven — from 20 records to 457 — so the confidence attached to each row differs by more than the rows differ from each other. The columns that actually separate these suppliers are recovered mass per vial, documentation and reproducibility, and they are on the comparison page.

Code	Legal name	Location	Est.	Reports	Batches	Median purity	IQR (pp)	Doc score	Storefront
Homopeptide	Hunan Aslsen Technology Co., Ltd.	Changsha, CN	—	457	71	99.32	0.85	85	homopeptide.net →
TFC	Tianjin Finder Chemical Co., Ltd.	Tianjin, CN	—	417	76	99.19	0.84	84	tfcpeptides.com →
WWB	Wuhan Wansheng Biotechnology Co., Ltd.	Wuhan, CN	—	398	66	99.37	0.62	92	wuhanwanshengbio.com →
GGPeps	Nantong Guangyuan Chemical Co., Ltd.	Nantong, CN	—	371	65	98.76	0.91	77	ggpeps.net →
QSC	Qingdao Sigma Chemical Co., Ltd.	Qingdao, CN	—	350	66	99.51	0.81	90	qingdaosigma.com →
WXT	WuXi TIDES (WuXi AppTec Testing Division)	Wuxi, CN	2002	301	51	98.51	1.08	69	wuxitides.net →
HJ	Hubei Jianxiang Bioscience Co., Ltd.	Xianning, CN	2015	247	39	99.09	0.99	83	hubeijianxiang.net →
HYB	Shenzhen Hybio Pharmaceutical Co., Ltd.	Shenzhen, CN	2003	241	40	99.37	0.89	89	hybiopharmaceutical.com →
QYB	ChinaPeptides Co., Ltd. (QYAOBIO)	Shanghai, CN	2008	236	39	99.54	0.63	91	qyaobiopeptides.com →
JEEP	Guangzhou JEEP Biotechnology Co., Ltd.	Guangzhou, CN	—	230	38	99.37	0.70	88	jeepbio.com →
MKM	Xi'an Mokemei Biotechnology Co., Ltd.	Xi'an, CN	2016	229	39	98.90	0.92	78	mokemeibiotechnology.com →
CPC	Chinese Peptide Company Co., Ltd.	Hangzhou, CN	2001	227	40	98.49	0.80	68	chinesepeptidecompany.net →
KP	Zhuhai Kerui Biotechnology Co., Ltd.	Zhuhai, CN	2016	223	40	98.51	0.94	74	keruipeptides.com →
SGN	Sangon Biotech (Shanghai) Co., Ltd.	Shanghai, CN	2004	221	37	98.58	0.86	72	sangonbio.com →
SSA	Shanghai Sigma-Audley New Material Technology Co., Ltd.	Shanghai, CN	2018	219	39	98.24	0.81	72	shanghaisigmaaudley.com →
PPG	PolyPeptide Group (Hangzhou) Co., Ltd.	Hangzhou, CN	2006	213	38	99.45	0.72	93	polypeptidegroup.net →
BCH	Bachem Holding (Suzhou) Co., Ltd.	Suzhou, CN	2003	209	39	98.32	1.11	67	bachemholding.com →
ERP	Shanghai ERP Biotechnology Co., Ltd.	Shanghai, CN	2018	205	38	99.03	0.72	80	erpbiotechnology.com →
SWB	Shanghai Wibson Biotechnology Co., Ltd.	Shanghai, CN	2019	204	38	98.95	0.98	80	shanghaiwibsonbiotechnology.net →
AMB	AmbioPharm, Inc.	Beijing, CN	2003	203	36	99.43	0.75	93	ambiopharm.net →
FGP	Flourishglobal Peptide Biotech (Chengdu) Co., Ltd.	Chengdu, CN	2019	200	39	99.62	0.61	90	flourishglobalpeptide.net →
ASY	Asymchem Laboratories (Tianjin) Co., Ltd.	Tianjin, CN	1998	190	34	99.59	0.82	96	asymchem.org →
TFS	Thermo Fisher Scientific (China) Co., Ltd.	Shanghai, CN	2006	188	33	99.24	0.89	95	thermofisherpeptides.com →
GSP	GenScript Biotech Corporation	Nanjing, CN	2002	180	32	99.02	1.00	91	genscriptpeptides.com →
SinoPep	SinoPep Biotechnology (Changzhou) Co., Ltd.	Changzhou, CN	2011	162	30	98.83	1.00	93	sinopep.net →
SIG	Sigma-Aldrich (Shanghai) Trading Co., Ltd.	Shanghai, CN	2005	160	30	98.57	0.86	91	sigmaaldrich.org →
GL Biochem	GL Biochem (Shanghai) Ltd.	Shanghai, CN	1998	83	17	98.81	0.53	71	glbiochem.net →
QST	Qingdao Saber Technology Pharmaceutical	Qingdao, CN	2017	20	4	98.17	0.43	65	qingdaosabertechnology.com →

The storefront column links each supplier's own shop, marked nofollow and sponsored, so a scorecard can be read against what the seller publishes. The index takes no payment for placement and a link is not an assessment. Suppliers below the scorecard threshold carry no link, which is the whole difference between the two lists on this page.

Figure. Purity distribution per supplier, ordered by coverage. Box spans Q1–Q3, heavy rule is the median, whiskers are the extreme observations inside 1.5 IQR, and points beyond the fences are drawn individually. The vertical line is the index median, 99.08 % area. Read the widths before the positions: the boxes overlap almost completely, and the suppliers that separate do so by having longer left tails rather than lower medians.

Homopeptide

Hunan Aslsen Technology Co., Ltd.

Changsha, CNhomopeptide.net

reports457

median %99.32

doc85

TFC

Tianjin Finder Chemical Co., Ltd.

Tianjin, CNtfcpeptides.com

reports417

median %99.19

doc84

WWB

Wuhan Wansheng Biotechnology Co., Ltd.

Wuhan, CNwuhanwanshengbio.com

reports398

median %99.37

doc92

GGPeps

Nantong Guangyuan Chemical Co., Ltd.

Nantong, CNggpeps.net

reports371

median %98.76

doc77

QSC

Qingdao Sigma Chemical Co., Ltd.

Qingdao, CNqingdaosigma.com

reports350

median %99.51

doc90

WXT

WuXi TIDES (WuXi AppTec Testing Division)

Wuxi, CNest. 2002wuxitides.net

reports301

median %98.51

doc69

HJ

Hubei Jianxiang Bioscience Co., Ltd.

Xianning, CNest. 2015hubeijianxiang.net

reports247

median %99.09

doc83

HYB

Shenzhen Hybio Pharmaceutical Co., Ltd.

Shenzhen, CNest. 2003hybiopharmaceutical.com

reports241

median %99.37

doc89

QYB

ChinaPeptides Co., Ltd. (QYAOBIO)

Shanghai, CNest. 2008qyaobiopeptides.com

reports236

median %99.54

doc91

JEEP

Guangzhou JEEP Biotechnology Co., Ltd.

Guangzhou, CNjeepbio.com

reports230

median %99.37

doc88

MKM

Xi'an Mokemei Biotechnology Co., Ltd.

Xi'an, CNest. 2016mokemeibiotechnology.com

reports229

median %98.90

doc78

CPC

Chinese Peptide Company Co., Ltd.

Hangzhou, CNest. 2001chinesepeptidecompany.net

reports227

median %98.49

doc68

KP

Zhuhai Kerui Biotechnology Co., Ltd.

Zhuhai, CNest. 2016keruipeptides.com

reports223

median %98.51

doc74

SGN

Sangon Biotech (Shanghai) Co., Ltd.

Shanghai, CNest. 2004sangonbio.com

reports221

median %98.58

doc72

SSA

Shanghai Sigma-Audley New Material Technology Co., Ltd.

Shanghai, CNest. 2018shanghaisigmaaudley.com

reports219

median %98.24

doc72

PPG

PolyPeptide Group (Hangzhou) Co., Ltd.

Hangzhou, CNest. 2006polypeptidegroup.net

reports213

median %99.45

doc93

BCH

Bachem Holding (Suzhou) Co., Ltd.

Suzhou, CNest. 2003bachemholding.com

reports209

median %98.32

doc67

ERP

Shanghai ERP Biotechnology Co., Ltd.

Shanghai, CNest. 2018erpbiotechnology.com

reports205

median %99.03

doc80

SWB

Shanghai Wibson Biotechnology Co., Ltd.

Shanghai, CNest. 2019shanghaiwibsonbiotechnology.net

reports204

median %98.95

doc80

AMB

AmbioPharm, Inc.

Beijing, CNest. 2003ambiopharm.net

reports203

median %99.43

doc93

FGP

Flourishglobal Peptide Biotech (Chengdu) Co., Ltd.

Chengdu, CNest. 2019flourishglobalpeptide.net

reports200

median %99.62

doc90

ASY

Asymchem Laboratories (Tianjin) Co., Ltd.

Tianjin, CNest. 1998asymchem.org

reports190

median %99.59

doc96

TFS

Thermo Fisher Scientific (China) Co., Ltd.

Shanghai, CNest. 2006thermofisherpeptides.com

reports188

median %99.24

doc95

GSP

GenScript Biotech Corporation

Nanjing, CNest. 2002genscriptpeptides.com

reports180

median %99.02

doc91

SinoPep

SinoPep Biotechnology (Changzhou) Co., Ltd.

Changzhou, CNest. 2011sinopep.net

reports162

median %98.83

doc93

SIG

Sigma-Aldrich (Shanghai) Trading Co., Ltd.

Shanghai, CNest. 2005sigmaaldrich.org

reports160

median %98.57

doc91

GL Biochem

GL Biochem (Shanghai) Ltd.

Shanghai, CNest. 1998glbiochem.net

reports83

median %98.81

doc71

QST

Qingdao Saber Technology Pharmaceutical

Qingdao, CNest. 2017qingdaosabertechnology.com

reports20

median %98.17

doc65

Block 4

Suppliers without a scorecard

Named in the trade and, in most cases, in this index’s own submission queue — but below the coverage at which any statistic here would mean anything.

A scorecard needs enough records to compute a median, a spread and a divergence figure that are not noise. The 188 suppliers below have not reached it. They are listed so the 28 above read as a coverage threshold rather than a shortlist. No scorecard, no rating, no outbound link.

Supplier	Band	Records seen	Note
Trusted Peptide	B	2	2 records, all in band B. Thin against the catalogue breadth: the tested lines are a small fraction of what is listed. Nothing further is claimed.
Risynth Bio	B	8	Band B on 8 reports. The individual records are worth more than any statistic over them at this count. Records are held and published; the summary is not.
NUPEPS Peptides	B	4	Banded B on a series of 4. The scorecard threshold is a coverage threshold and this row is short of it, which is all the row asserts. Nothing further is claimed.
Hunan GoodPeptides Biotech Co	B	2	Band B, evidence base 2 reports. A band on this many observations is a first impression rather than a characterisation. Records are held and published; the summary is not.
Bulk Peptide Wholesale	B	20	20 indexed results and a stable band B. The series is long enough to have a shape and the shape sits below the band the twenty scorecarded suppliers occupy. Listed for coverage, not assessed.
Paradigm Peptide	B	16	16 records on file and the band has not moved off B. The certificates behind these records do not stand on their own: totals without named related substances, results without methods. Absence of a scorecard is not a negative finding.
Orbitrex Peptides	B	17	17 indexed results and a stable band B. Nothing about the series is erratic. It is simply banded below the threshold this index draws its scorecard line at. Absence of a scorecard is not a negative finding.
Aavant Research	B	13	Band B across 13 indexed results. Reports are consistent with each other and consistently below the range the scorecarded suppliers occupy. Presence here is a statement about how many records the index holds.
PeptiAtlas	B	4	4 indexed results, banded B. Below the coverage at which a median, an interquartile range and a divergence figure stop being noise, which is where the scorecard threshold sits.
The Naughty Needle	B	2	Banded B on a series of 2. A band on this many observations is a first impression rather than a characterisation.
Lux Synth Aminos	B	2	2 reports on file, band B throughout. No reproducibility figure is computable, because that needs repeat assays on the same lot and none are on file. Records are held and published; the summary is not.
Huaian Hanyou Peptide	B	7	Band B on 7 reports. Thin against the catalogue breadth: the tested lines are a small fraction of what is listed. Nothing further is claimed.
Lisa Biopeptide	B	11	Band B across 11 indexed results. Level is legible, provenance is not: the index cannot say how many of these samples were independently purchased. The individual records remain in the dataset.
Lipeptides	B	7	Band B on 7 reports. The individual records are worth more than any statistic over them at this count. Nothing further is claimed.
NextGen Health	B	3	Banded B on a series of 3. Thin against the catalogue breadth: the tested lines are a small fraction of what is listed. The row is the whole entry; there is no profile behind it.
OmegAmino	B	4	4 records, all in band B. Enough to see a level and not enough to see a distribution around it. The row is the whole entry; there is no profile behind it.
Xianhong Tong XHT Peptides	B	5	Band B, evidence base 5 reports. Enough for a band and not enough for the columns that actually separate suppliers.
Diju Peptides Wellness and Co	B	4	4 indexed results, banded B. Enough to see a level and not enough to see a distribution around it.
Zhang TY	B	4	Band B, evidence base 4 reports. Enough to see a level and not enough to see a distribution around it.
SubQ Society	B	3	Band B on 3 reports. Below the coverage at which a median, an interquartile range and a divergence figure stop being noise, which is where the scorecard threshold sits. No scorecard, no rating, no outbound link.
Bfflink	B	13	Band B across 13 indexed results. A supplier can be entirely consistent at a level below the one a scorecard would flatter, and this is what that looks like. The row is the whole entry; there is no profile behind it.
Laicuinuo LCN	B	7	7 indexed results, banded B. Enough for a band and not enough for the columns that actually separate suppliers. Records are held and published; the summary is not.
Cellupep	B	7	Band B on 7 reports. Enough to see a level and not enough to see a distribution around it. The individual records remain in the dataset.
Shanghai Leader Peptide Biotechnology	B	8	8 indexed results, banded B. Thin against the catalogue breadth: the tested lines are a small fraction of what is listed.
Peptronix Bio PTB	B	13	Band B across 13 indexed results. Where a certificate states a result and no method, there is nothing for an independent figure to be reconciled against, and that is the pattern here. Listed for coverage, not assessed.
Yongkang Nuoao Trading Co	B	9	Banded B on a series of 9. The individual records are worth more than any statistic over them at this count. No scorecard, no rating, no outbound link.
Eros Peptides	B	3	Band B, evidence base 3 reports. The scorecard threshold is a coverage threshold and this row is short of it, which is all the row asserts.
Champion Peptide	B	6	6 indexed results, banded B. The point estimate is unstable: two more records could move it by more than the whole tier-1 spread.
Bio Pepz	B	4	Band B on 4 reports. The point estimate is unstable: two more records could move it by more than the whole tier-1 spread. No scorecard, no rating, no outbound link.
Shandong Nuoweiou Medical Technology Co	B	5	Banded B on a series of 5. The scorecard threshold is a coverage threshold and this row is short of it, which is all the row asserts.
PurePEPS	B	4	Band B, evidence base 4 reports. The scorecard threshold is a coverage threshold and this row is short of it, which is all the row asserts. The individual records remain in the dataset.
Rayshine Peptide Biochemicals	C	6	6 reports on file, band C throughout. Thin against the catalogue breadth: the tested lines are a small fraction of what is listed. The individual records remain in the dataset.
HealthTide Biotech	C	6	6 records, all in band C. The individual records are worth more than any statistic over them at this count. The row is the whole entry; there is no profile behind it.
Dankang BioHealth	C	12	Band C, 12 reports, no movement across the series. Enough records to be confident about the level, which is the reason the row exists rather than a reason to expand it. The row is the whole entry; there is no profile behind it.
Kits4less	C	7	7 reports on file, band C throughout. The point estimate is unstable: two more records could move it by more than the whole tier-1 spread. The row is the whole entry; there is no profile behind it.
Huayi Biotechnology	C	19	A 19-report series, band C. A stable band is a real finding. It is not a high one, and it is why no scorecard is computed. Presence here is a statement about how many records the index holds.
Anlv Biotechnology	C	10	Band C, 10 reports, no movement across the series. Where a certificate states a result and no method, there is nothing for an independent figure to be reconciled against, and that is the pattern here. Listed for coverage, not assessed.
Xingtai Pukelai Technology Co	C	6	6 indexed results, banded C. Enough for a band and not enough for the columns that actually separate suppliers.
EHZ Peptides	C	39	39 indexed results and a stable band C. The series is long enough to have a shape and the shape sits below the band the twenty scorecarded suppliers occupy. The row is the whole entry; there is no profile behind it.
Zztai Peptide	C	30	A 30-report series, band C. A supplier can be entirely consistent at a level below the one a scorecard would flatter, and this is what that looks like. The row is the whole entry; there is no profile behind it.
Chimera Peptides	C	8	8 records, all in band C. The individual records are worth more than any statistic over them at this count. Nothing further is claimed.
Hangzhou Mandy Biotechnology	C	14	A 14-report series, band C. A stable band is a real finding. It is not a high one, and it is why no scorecard is computed. Absence of a scorecard is not a negative finding.
Yabang Peptide	C	10	A 10-report series, band C. Nothing about the series is erratic. It is simply banded below the threshold this index draws its scorecard line at.
Evolve BioPep	C	7	Band C on 7 reports. No reproducibility figure is computable, because that needs repeat assays on the same lot and none are on file.
Quenna PMQ	D	15	A 15-report series, band D. The certificates behind these records do not stand on their own: totals without named related substances, results without methods. No scorecard, no rating, no outbound link.
Nanjing Xiyuxun Technology XYX	D	3	3 indexed results, banded D. A band on this many observations is a first impression rather than a characterisation. The individual records remain in the dataset.
Welon Peptide Solutions	D	5	Band D, evidence base 5 reports. Thin against the catalogue breadth: the tested lines are a small fraction of what is listed. Presence here is a statement about how many records the index holds.
Xingtai Lesda Technology	E	6	6 records, all in band E. A band on this many observations is a first impression rather than a characterisation. The individual records remain in the dataset.
Qingdao Hongshengda Trading	E	4	Band E on 4 reports. Thin against the catalogue breadth: the tested lines are a small fraction of what is listed. Presence here is a statement about how many records the index holds.
ZZQ Peptides	E	22	22 records on file and the band has not moved off E. Where a certificate states a result and no method, there is nothing for an independent figure to be reconciled against, and that is the pattern here. Nothing further is claimed.
Changan District Sheng Peptide Trading	E	7	7 indexed results, banded E. The point estimate is unstable: two more records could move it by more than the whole tier-1 spread. Records are held and published; the summary is not.
UWA Elite Peptides	E	16	16 records on file and the band has not moved off E. Coverage is adequate; what is missing is the documentation that would let any of it be reconciled — method, related substances, content basis. Nothing further is claimed.
Hangzhou Youngpeptide Biotechnology HYB	E	15	A 15-report series, band E. Level is legible, provenance is not: the index cannot say how many of these samples were independently purchased. Listed for coverage, not assessed.
Modern Aminos	E	4	Band E, evidence base 4 reports. Thin against the catalogue breadth: the tested lines are a small fraction of what is listed. No scorecard, no rating, no outbound link.
Shanghai OuDaXin New Material Technology Center	E	43	Band E, 43 reports, no movement across the series. The certificates behind these records do not stand on their own: totals without named related substances, results without methods. Records are held and published; the summary is not.
Shenzhen Jiechuang Trading	E	8	8 reports on file, band E throughout. Thin against the catalogue breadth: the tested lines are a small fraction of what is listed.
Shaanxi Dideu Medichem	E	6	6 reports on file, band E throughout. The individual records are worth more than any statistic over them at this count. Presence here is a statement about how many records the index holds.
Qingdao VitaConin International Trading	E	5	Band E, evidence base 5 reports. Enough for a band and not enough for the columns that actually separate suppliers.
Guangzhou Lengiuanhuang Cosmetics	E	4	4 indexed results, banded E. Enough for a band and not enough for the columns that actually separate suppliers. Presence here is a statement about how many records the index holds.
Shanghai JinBei Chemical Technology	B	18	Band B across 18 indexed results. The certificates behind these records do not stand on their own: totals without named related substances, results without methods. The individual records remain in the dataset.
Peptide Technologies	B	11	11 reports, consistently in band B. Where a certificate states a result and no method, there is nothing for an independent figure to be reconciled against, and that is the pattern here. Presence here is a statement about how many records the index holds.
Pura Peptides	X	1	Unbanded. 1 record indexed, which is below the count at which a band means anything. The honest statement is that the index does not know, and that is what this row records. Presence here is a statement about how many records the index holds.
Peptide Partners	B to C	64	64 reports spanning B to C. The spread is real and unexplained. Documentation on the records does not distinguish process variation from method difference. Absence of a scorecard is not a negative finding.
Bfflist AMO	B to C	63	Band B to C — that is a range, not a grade — over 63 reports. A supplier whose results span bands is a supplier whose next lot is not predictable from its last, and no scorecard fixes that.
Pure Tested Peptides	B to C	7	7 indexed results, B to C. Between-lot variance dominates. A median over this series would describe none of the lots in it. Absence of a scorecard is not a negative finding.
PeptiSlim	C to E	38	38 indexed results, C to E. Between-lot variance dominates. A median over this series would describe none of the lots in it. Presence here is a statement about how many records the index holds.
Glamgurcraft Innovations Foreign Trade	X	1	The directory lists this supplier with no band and 1 report behind it. Absence of a band is not a negative finding. It is an absence, and it is stated as one. No scorecard, no rating, no outbound link.
HkRoids	B to C	14	14 reports spanning B to C. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. Presence here is a statement about how many records the index holds.
Yiwu Aozuo Trading Co	B to E	91	91 records and the band is quoted as a span: B to E. The spread is real and unexplained. Documentation on the records does not distinguish process variation from method difference. No scorecard, no rating, no outbound link.
Peptide Haven	B	4	Band B, evidence base 4 reports. Thin against the catalogue breadth: the tested lines are a small fraction of what is listed. The individual records remain in the dataset.
Atomik Labz	B to C	40	Band B to C — that is a range, not a grade — over 40 reports. Between-lot variance dominates. A median over this series would describe none of the lots in it.
Bulk Peptide Supply	B to E	20	A 20-report series that spans B to E. Wide dispersion with no reproducibility data behind it: no lot in this series has been assayed more than once. Listed for coverage, not assessed.
M-Peptides	B to C	17	A 17-report series that spans B to C. Two lots from this series could differ by more than the entire spread of the twenty scorecarded suppliers.
Mai Peptide	C to E	55	A 55-report series that spans C to E. Two lots from this series could differ by more than the entire spread of the twenty scorecarded suppliers. Absence of a scorecard is not a negative finding.
Peptidology	B	16	16 reports, consistently in band B. Enough records to be confident about the level, which is the reason the row exists rather than a reason to expand it. No scorecard, no rating, no outbound link.
Hazel	X	1	The directory lists this supplier with no band and 1 report behind it. Coverage this thin is a statement about who has submitted, not about who is selling. The row is the whole entry; there is no profile behind it.
TCI	X	1	Carried without a band: 1 record is not a distribution. The index publishes what it holds and holds too little here to summarise. No scorecard, no rating, no outbound link.
Uther	B to E	69	Band B to E — that is a range, not a grade — over 69 reports. Two lots from this series could differ by more than the entire spread of the twenty scorecarded suppliers. Nothing further is claimed.
Shandong Shengyuan Peptide Technology	B to E	24	24 records and the band is quoted as a span: B to E. Wide dispersion with no reproducibility data behind it: no lot in this series has been assayed more than once.
LiliPeptide	C to E	185	185 reports spanning C to E. A span rather than a grade. That is a finding about consistency and it is the reason no single figure is published. The row is the whole entry; there is no profile behind it.
Xingruida XDR	B to D	64	A 64-report series that spans B to D. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. Records are held and published; the summary is not.
Eternal Peptides	B	23	Band B, 23 reports, no movement across the series. The certificates behind these records do not stand on their own: totals without named related substances, results without methods. No scorecard, no rating, no outbound link.
Tianjin Ruiwang New Material Technology Co	B to E	107	107 records and the band is quoted as a span: B to E. Wide dispersion with no reproducibility data behind it: no lot in this series has been assayed more than once. The individual records remain in the dataset.
Polaris Peptides	B to D	97	Band B to D — that is a range, not a grade — over 97 reports. A span rather than a grade. That is a finding about consistency and it is the reason no single figure is published. The row is the whole entry; there is no profile behind it.
Injectify	B to E	29	A 29-report series that spans B to E. Where a series straddles bands the useful question is which lot you are being offered, and the index cannot answer it from here.
Precision Peptide Co	B to C	21	21 reports spanning B to C. Between-lot variance dominates. A median over this series would describe none of the lots in it. Records are held and published; the summary is not.
AKS Chem	X	1	The directory lists this supplier with no band and 1 report behind it. A single-figure series is an anecdote about a vial rather than a finding about a company, and the index will not compute a median over it. Presence here is a statement about how many records the index holds.
Reta-Peptide	B to E	144	144 reports spanning B to E. Between-lot variance dominates. A median over this series would describe none of the lots in it. Nothing further is claimed.
Peptide-S	B to E	125	125 reports spanning B to E. Wide dispersion with no reproducibility data behind it: no lot in this series has been assayed more than once. Records are held and published; the summary is not.
Planet Peptide	B to D	59	59 indexed results, B to D. The spread is real and unexplained. Documentation on the records does not distinguish process variation from method difference. Listed for coverage, not assessed.
Henan Sahe Peptide	B to D	18	18 indexed results, B to D. Wide dispersion with no reproducibility data behind it: no lot in this series has been assayed more than once. Presence here is a statement about how many records the index holds.
Hunan Ruiwang Technology Center	B to C	14	14 records and the band is quoted as a span: B to C. The index will not average across a range this wide, because the average would be a number no vial in the series resembles.
Skye Peptides	B to E	73	A 73-report series that spans B to E. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. The individual records remain in the dataset.
Nuscience Peptides	B to D	47	47 records and the band is quoted as a span: B to D. The index will not average across a range this wide, because the average would be a number no vial in the series resembles. Presence here is a statement about how many records the index holds.
NextechLabs	B to D	30	30 reports spanning B to D. The spread is real and unexplained. Documentation on the records does not distinguish process variation from method difference. The row is the whole entry; there is no profile behind it.
Golden Eagle	B to C	17	17 reports spanning B to C. A span rather than a grade. That is a finding about consistency and it is the reason no single figure is published. Listed for coverage, not assessed.
Peptide Worldwide	X	1	Carried without a band: 1 record is not a distribution. No scorecard follows, because a scorecard over this many observations would be decoration. Records are held and published; the summary is not.
HK Peptides	B to E	343	A 343-report series that spans B to E. The spread is real and unexplained. Documentation on the records does not distinguish process variation from method difference. Listed for coverage, not assessed.
Nexaph	B to E	200	Results range across B to E over 200 records. Where a series straddles bands the useful question is which lot you are being offered, and the index cannot answer it from here. Listed for coverage, not assessed.
BeiBangAn	C to D	38	38 indexed results, C to D. Wide dispersion with no reproducibility data behind it: no lot in this series has been assayed more than once.
Shandong Aishi Biotechnology	D to E	37	37 reports spanning D to E. Where a series straddles bands the useful question is which lot you are being offered, and the index cannot answer it from here. Nothing further is claimed.
Xingtai Jiachuang Technology	C to E	31	A 31-report series that spans C to E. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. The individual records remain in the dataset.
Zenith Jove Peptide ZJ	B to E	26	Results range across B to E over 26 records. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. Presence here is a statement about how many records the index holds.
Kerisite Shenzhen International	B to D	16	16 indexed results, B to D. A span rather than a grade. That is a finding about consistency and it is the reason no single figure is published. Nothing further is claimed.
YB Peptide	B to E	10	10 records and the band is quoted as a span: B to E. The index will not average across a range this wide, because the average would be a number no vial in the series resembles. No scorecard, no rating, no outbound link.
Qing Li Peptide	B to E	260	260 indexed results, B to E. Dispersion rather than location is the operative statistic here: results land in more than one band, so a central value would conceal the thing worth knowing. Absence of a scorecard is not a negative finding.
Shanxi Qianyecao Biotech QYC	D to E	66	66 records and the band is quoted as a span: D to E. Where a series straddles bands the useful question is which lot you are being offered, and the index cannot answer it from here. No scorecard, no rating, no outbound link.
Verified Peptides	B to C	34	34 records and the band is quoted as a span: B to C. The index will not average across a range this wide, because the average would be a number no vial in the series resembles. Listed for coverage, not assessed.
Hebei Rimao Technology	C to D	32	A 32-report series that spans C to D. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. Presence here is a statement about how many records the index holds.
Pure Rawz	B to D	29	29 reports spanning B to D. Dispersion rather than location is the operative statistic here: results land in more than one band, so a central value would conceal the thing worth knowing. Listed for coverage, not assessed.
Heman Peptide HM	B to E	29	29 reports spanning B to E. A supplier whose results span bands is a supplier whose next lot is not predictable from its last, and no scorecard fixes that. The individual records remain in the dataset.
Shanghai Baoju	B to E	21	Band B to E — that is a range, not a grade — over 21 reports. Between-lot variance dominates. A median over this series would describe none of the lots in it. No scorecard, no rating, no outbound link.
ZLZ Peptide	B to E	199	199 records and the band is quoted as a span: B to E. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains.
Peptide Sciences	B to E	123	123 records and the band is quoted as a span: B to E. The spread is real and unexplained. Documentation on the records does not distinguish process variation from method difference. Listed for coverage, not assessed.
Allen Biotechnology Co ABC	B to E	43	43 records and the band is quoted as a span: B to E. A supplier whose results span bands is a supplier whose next lot is not predictable from its last, and no scorecard fixes that. The individual records remain in the dataset.
Peptide Crafters	B to D	39	A 39-report series that spans B to D. A supplier whose results span bands is a supplier whose next lot is not predictable from its last, and no scorecard fixes that. Records are held and published; the summary is not.
Simple Peptide	B to D	26	26 records and the band is quoted as a span: B to D. Wide dispersion with no reproducibility data behind it: no lot in this series has been assayed more than once. Records are held and published; the summary is not.
Top Peptide	C to D	21	21 records and the band is quoted as a span: C to D. Between-lot variance dominates. A median over this series would describe none of the lots in it. Nothing further is claimed.
Zen Peptides	B to C	13	13 indexed results, B to C. Where a series straddles bands the useful question is which lot you are being offered, and the index cannot answer it from here. Nothing further is claimed.
Amino Lair	B to D	12	12 indexed results, B to D. A supplier whose results span bands is a supplier whose next lot is not predictable from its last, and no scorecard fixes that. The row is the whole entry; there is no profile behind it.
Oupeptide	B to E	149	Results range across B to E over 149 records. Two lots from this series could differ by more than the entire spread of the twenty scorecarded suppliers.
Paramount Peptides	B to E	65	A 65-report series that spans B to E. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. The individual records remain in the dataset.
Yimei	B to E	54	Results range across B to E over 54 records. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains.
LSPL	C to E	40	A 40-report series that spans C to E. Between-lot variance dominates. A median over this series would describe none of the lots in it. Nothing further is claimed.
Royal Peptides	B to C	30	30 records and the band is quoted as a span: B to C. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. Nothing further is claimed.
Shenzhen Loga Tech LG LOGA	B to E	21	Results range across B to E over 21 records. Two lots from this series could differ by more than the entire spread of the twenty scorecarded suppliers. The individual records remain in the dataset.
ZhuoYan lab	C to E	30	Results range across C to E over 30 records. Where a series straddles bands the useful question is which lot you are being offered, and the index cannot answer it from here. Nothing further is claimed.
Astro Peptides	B to E	29	29 indexed results, B to E. Where a series straddles bands the useful question is which lot you are being offered, and the index cannot answer it from here. The individual records remain in the dataset.
Mix Peptides	D to E	29	Band D to E — that is a range, not a grade — over 29 reports. Wide dispersion with no reproducibility data behind it: no lot in this series has been assayed more than once. Records are held and published; the summary is not.
Science	B to C	12	12 reports spanning B to C. The spread is real and unexplained. Documentation on the records does not distinguish process variation from method difference.
TSC Top Supplements China	C to E	99	Band C to E — that is a range, not a grade — over 99 reports. The index will not average across a range this wide, because the average would be a number no vial in the series resembles. Listed for coverage, not assessed.
HXNet	C to E	91	Band C to E — that is a range, not a grade — over 91 reports. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. Presence here is a statement about how many records the index holds.
Xian Yihang Technology	C to E	48	48 records and the band is quoted as a span: C to E. A supplier whose results span bands is a supplier whose next lot is not predictable from its last, and no scorecard fixes that.
Haikou Mingheng Technology	B to C	16	16 indexed results, B to C. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. Listed for coverage, not assessed.
SRY Labs	B to E	111	111 reports spanning B to E. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains.
Accelerate Labs	B to E	20	A 20-report series that spans B to E. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. Listed for coverage, not assessed.
PurePeptides	B to E	15	Band B to E — that is a range, not a grade — over 15 reports. A supplier whose results span bands is a supplier whose next lot is not predictable from its last, and no scorecard fixes that. No scorecard, no rating, no outbound link.
Regenerative Research	X	2	Carried without a band: 2 records is not a distribution. Whether the material is good is an open question and this row does not answer it in either direction. No scorecard, no rating, no outbound link.
Zhejiang Yichenkang Biotechnology	B to E	58	58 indexed results, B to E. The spread is real and unexplained. Documentation on the records does not distinguish process variation from method difference. The individual records remain in the dataset.
Biolongevity Labs	B to E	33	Band B to E — that is a range, not a grade — over 33 reports. Where a series straddles bands the useful question is which lot you are being offered, and the index cannot answer it from here. Presence here is a statement about how many records the index holds.
Alpha-Gen	B to E	30	30 reports spanning B to E. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. No scorecard, no rating, no outbound link.
LN Peptides	B to E	28	A 28-report series that spans B to E. A span rather than a grade. That is a finding about consistency and it is the reason no single figure is published. Presence here is a statement about how many records the index holds.
Forever Young Pharmacy	B to E	26	26 records and the band is quoted as a span: B to E. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. Listed for coverage, not assessed.
Prime Peptides	B to E	19	A 19-report series that spans B to E. A supplier whose results span bands is a supplier whose next lot is not predictable from its last, and no scorecard fixes that. Records are held and published; the summary is not.
Haikou Mingheng Biotechnology	D to E	11	11 records and the band is quoted as a span: D to E. Where a series straddles bands the useful question is which lot you are being offered, and the index cannot answer it from here. Records are held and published; the summary is not.
Dragon Pharma	X	1	Carried without a band: 1 record is not a distribution. The honest statement is that the index does not know, and that is what this row records. Presence here is a statement about how many records the index holds.
Liberty Peptides	B to E	16	Band B to E — that is a range, not a grade — over 16 reports. The index will not average across a range this wide, because the average would be a number no vial in the series resembles. The individual records remain in the dataset.
Amino Asylum	B to C	15	A 15-report series that spans B to C. Wide dispersion with no reproducibility data behind it: no lot in this series has been assayed more than once.
Amino Amigos	B to E	37	37 reports spanning B to E. Between-lot variance dominates. A median over this series would describe none of the lots in it.
Platinum Cryo	B to E	24	24 records and the band is quoted as a span: B to E. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. Presence here is a statement about how many records the index holds.
Elite Research USA	B to E	47	47 indexed results, B to E. Wide dispersion with no reproducibility data behind it: no lot in this series has been assayed more than once. Absence of a scorecard is not a negative finding.
Limitless Life Nootropics	B to D	22	22 records and the band is quoted as a span: B to D. Two lots from this series could differ by more than the entire spread of the twenty scorecarded suppliers. Presence here is a statement about how many records the index holds.
Oasis Peptides	B to E	16	A 16-report series that spans B to E. Where a series straddles bands the useful question is which lot you are being offered, and the index cannot answer it from here.
Suaway Lab Research	B to E	39	39 records and the band is quoted as a span: B to E. A span rather than a grade. That is a finding about consistency and it is the reason no single figure is published.
Pharma Grade Peptides	B to E	18	18 reports spanning B to E. Where a series straddles bands the useful question is which lot you are being offered, and the index cannot answer it from here. Records are held and published; the summary is not.
PeptiLab Research	B to E	15	15 indexed results, B to E. Wide dispersion with no reproducibility data behind it: no lot in this series has been assayed more than once. Records are held and published; the summary is not.
Tydes	C to E	41	41 indexed results, C to E. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. Listed for coverage, not assessed.
Loti Labs	B to E	32	Results range across B to E over 32 records. A span rather than a grade. That is a finding about consistency and it is the reason no single figure is published.
Wolverine Peptides	X	1	Carried without a band: 1 record is not a distribution. A single-figure series is an anecdote about a vial rather than a finding about a company, and the index will not compute a median over it. Nothing further is claimed.
Amplified Amino	C to E	12	A 12-report series that spans C to E. The spread is real and unexplained. Documentation on the records does not distinguish process variation from method difference. Listed for coverage, not assessed.
Alimo Peptide	D to E	7	7 indexed results, D to E. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains.
Richards Biotech Simply Richards	X	1	The directory lists this supplier with no band and 1 report behind it. Whether the material is good is an open question and this row does not answer it in either direction. Nothing further is claimed.
Coastal Peptides	B to E	26	26 records and the band is quoted as a span: B to E. Wide dispersion with no reproducibility data behind it: no lot in this series has been assayed more than once. Absence of a scorecard is not a negative finding.
Peptides 4 Research	C to E	20	A 20-report series that spans C to E. Results spanning more than one band mean lot-to-lot variation exceeds anything measurement error explains. The individual records remain in the dataset.
Deuschem	B to E	29	Results range across B to E over 29 records. A supplier whose results span bands is a supplier whose next lot is not predictable from its last, and no scorecard fixes that. Records are held and published; the summary is not.
Hybiopeptides	X	1	1 report on file and no band assigned in the source directory. Absence of a band is not a negative finding. It is an absence, and it is stated as one. Nothing further is claimed.
Peptide Gurus	B to E	45	Band B to E — that is a range, not a grade — over 45 reports. Wide dispersion with no reproducibility data behind it: no lot in this series has been assayed more than once. Presence here is a statement about how many records the index holds.
Swiss Chems	C to E	9	A 9-report series that spans C to E. The spread is real and unexplained. Documentation on the records does not distinguish process variation from method difference. The individual records remain in the dataset.
WllyBIO	X	1	No band assigned. The evidence base is 1 report. Whether the material is good is an open question and this row does not answer it in either direction.
Biolabshop Limited	C to E	6	Band C to E — that is a range, not a grade — over 6 reports. A span rather than a grade. That is a finding about consistency and it is the reason no single figure is published. Absence of a scorecard is not a negative finding.
Peptides For Sale	D to E	21	Results range across D to E over 21 records. Two lots from this series could differ by more than the entire spread of the twenty scorecarded suppliers.
NuLife Peptides	B	6	6 records, all in band B. The point estimate is unstable: two more records could move it by more than the whole tier-1 spread. The row is the whole entry; there is no profile behind it.
Wuhan Newtop Biotech	X	2	The directory lists this supplier with no band and 2 reports behind it. Whether the material is good is an open question and this row does not answer it in either direction. Listed for coverage, not assessed.
LOOKBiotech	X	2	2 reports on file and no band assigned in the source directory. The index publishes what it holds and holds too little here to summarise. The individual records remain in the dataset.
PRIVATE	X	2	The directory lists this supplier with no band and 2 reports behind it. Nothing here conflicts with anything else; there is simply not enough of it to conflict with. Presence here is a statement about how many records the index holds.
Peptide Ark	X	2	The directory lists this supplier with no band and 2 reports behind it. No scorecard follows, because a scorecard over this many observations would be decoration. Listed for coverage, not assessed.
Zhuoyue Biotechnology	X	1	1 indexed result, unbanded at source and unbanded here. No scorecard follows, because a scorecard over this many observations would be decoration. The row is the whole entry; there is no profile behind it.
Hebei Chengtong Technology	X	1	Carried without a band: 1 record is not a distribution. No scorecard follows, because a scorecard over this many observations would be decoration.
Coffee and Peppers	X	1	The directory lists this supplier with no band and 1 report behind it. The honest statement is that the index does not know, and that is what this row records. Listed for coverage, not assessed.
Marvel Peptide	X	1	No band assigned. The evidence base is 1 report. No scorecard follows, because a scorecard over this many observations would be decoration. The individual records remain in the dataset.
HK Fat Cat	X	1	The directory lists this supplier with no band and 1 report behind it. A single-figure series is an anecdote about a vial rather than a finding about a company, and the index will not compute a median over it. Records are held and published; the summary is not.
Guangzhou Yuao Trading	X	1	Unbanded. 1 record indexed, which is below the count at which a band means anything. The index publishes what it holds and holds too little here to summarise.
PepKits	X	1	The directory lists this supplier with no band and 1 report behind it. One or two results tell you about one or two vials. They do not generalise and the index does not pretend otherwise.
Lejian Biotech Peptide	X	1	1 indexed result, unbanded at source and unbanded here. Whether the material is good is an open question and this row does not answer it in either direction.
PepLab Solutions	X	1	1 report on file and no band assigned in the source directory. Absence of a band is not a negative finding. It is an absence, and it is stated as one. Listed for coverage, not assessed.
Explicit Sarms	X	1	1 indexed result, unbanded at source and unbanded here. The index publishes what it holds and holds too little here to summarise. Listed for coverage, not assessed.
Weifang Xingbei International Trade	X	1	1 indexed result, unbanded at source and unbanded here. The index publishes what it holds and holds too little here to summarise.
Advanced Technology and Industrial	X	1	Carried without a band: 1 record is not a distribution. No scorecard follows, because a scorecard over this many observations would be decoration. No scorecard, no rating, no outbound link.

Presence here is a statement about how many records the index holds, not an assessment. Absence of a scorecard is not a negative finding.